Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity, tolerability, and manufacturing consistency of a 9-valent HPV L1 VLP vaccine in 9–15-year-olds and 16–26-year-old women
2009-011617-25Phase 3Completed
- Sponsor
- MSD
- Start
- Jul 2009
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of recombinant human papillomavirus 9-valent vaccine in Cervical Cancer (CC) (2 cohorts), sponsored by MSD. Primary endpoints: Tolerability of the 9-valent HPV L1 VLP vaccine, Immunogenicity of the 9-valent HPV L1 VLP vaccine and 1 more. Started Jul 2009; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2009-011617-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011617-25.